ZomedicPharmaceuticals is a client of PCG Advisory, Inc., an investor relations and communications firm. Please see our disclosures in the research report as well as on our website www.pcgadvisory.com.

Download the PCG Zomedica Report

Learn More about Zomedica by gaining access to the latest Initiation report 

PCG REPORT

Your ticket to the latest on Zomedica

Our pets mean the world to us, and, for 9 out of every 10 Americans, they are just as much a member of our family as our siblings, parents, and children. Because of our enduring love for them, we do our best to provide great medical care, and the veterinary industry earns an incredible $50 billion dollars a year as a result.

When our pets do get sick, Zomedica plans to step in with innovative solutions, cutting-edge products, and teams who love their animals as much as the rest of us.

Want to learn more about Zomedica’s future plans? Download the Research Report on Zomedica to get extensive value on key investor areas, including clinical research reporting results

Zomedica is an industry-leading development-stage company, with plans to deliver solutions through a diverse pipeline of diagnostics and treatments for companion animal conditions.

Zomedica Aims to Fill Market Need for Treating Companion Animals in Diagnostics and Therapeutics

Home to a robust pipeline of animal diagnostics and therapeutics solutions focused on developing solutions for previously unmet needs.

With a market cap of under $40 million coupled with a robust pipeline and revenue potential in 2020, Zomedica is worthy of serious investor attention

Zomedica employs experienced doctors & veterinarians with decades of industry experience leading large cap companies. While still growing, Zomedica’s management and leadership teams plan to move aggressively towards revenue realization in 2020.

The Market is Hungry for Unique Solutions- $10 Billion Dollars and growing

Zomedica has an unrivaled market opportunity within the $2.6B global companion animal diagnostics market with that expected to grow at a CAGR of nearly 10% through 2024 to $10B and beyond.

Zomedica Prepared for Revenue in 2020

Zomedica and its partners owns 100 patents for hardware and software in the animal space.

Zomedica is nearing launch for many of the products in its diagnostic and therapeutics pipelines.

TRUFORMA is Zomedia’s flagship product that is expected to launch in 2020 alongside a digital customer data platform which will connect the line of products and the company’s diagnostic pipeline. The digital data platform will support veterinary teams with clinically relevant business services, including inventory management and key performance metrics.

TRUFORMA™ is used to detect thyroid & adrenal disorders in dogs and cats in as little as 15 minutes.  It is comprised of a table-top instrument that uses disposable assay cartridges to test a range of samples including whole blood, serum, and plasma.  Feasibility data has been achieved & complete assay validation along with revenue are both expected in 2020.

TRUFORMA™ is expected to deliver several milestones in 2020, inclusive of product launch in select target markets, international expansion of TRUFORMA, and the marketing of two first-ever point-of-care assays


Download the PCG Report on Zomedica to learn more about TRUFORMA™ and Zomedica’s go-to-market assays.

ZomedicPharmaceuticals is a client of PCG Advisory, Inc., an investor relations and communications firm. Please see our disclosures in the research report as well as on our website www.pcgadvisory.com.

DOWNLOAD

Driven by long-term and short-term growth

Zomedica is much like human pharmaceutical companies focusing on innovation, but unlike human pharmaceuticals have less red tape due to lesser FDA and governmental involvement which allows for shorter pipelines that are faster to market.

By focusing on an unmet need and creating real products backed by real data and validation of assays, Zomedica has a robust, diverse, and full pipeline that is ready to shake up an ever-growing industry.

Zomedica partnerships leverage relationships with Qorvo, Seraph Biosciences, and Celsee to advance products toward a global market opportunity.

Little to no pre-market regulatory for diagnostic platforms, allows for a faster moving pipeline

Diagnostics are the fastest growing sector in animal health with very few competitors

Revenue potential in 2020 with the launch of many validated products



A seasoned financial leader in the healthcare sector with 20 years of experience, Shameze Rampertab is a master of capital markets, strategic planning and financial analysis. Over the course of his distinctive and accomplished career, he successfully served as chief financial officer for multiple publicly traded healthcare startups, worked as an investment banker, thrived as a sell-side health-equity research analyst, and raised over $480 million of private and public capital. Before joining Zomedica, Shameze served as CFO and secretary at Profound Medical Corp. where he spearheaded a Qualifying Transaction with a Capital Pool Corporation resulting in the listing of shares on the TSX Venture Exchange. Prior to that, he was CFO and Vice President of Finance for Intellipharmaceutics International Inc., a NADSAQ and TSX listed pharmaceutical company. 

About the CEO

Download the PCG Zomedica report

ZomedicPharmaceuticals is a client of PCG Advisory, Inc., an investor relations and communications firm. Please see our disclosures in the research report as well as on our website www.pcgadvisory.com.

Reasons to Consider Zomedica

DOWNLOAD